BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 6,628 Shares of Edwards Lifesciences Co. (NYSE:EW)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 0.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,043,761 shares of the medical research company’s stock after selling 6,628 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.17% of Edwards Lifesciences worth $68,878,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its holdings in shares of Edwards Lifesciences by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after acquiring an additional 809,605 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Edwards Lifesciences by 57.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after purchasing an additional 2,390,137 shares during the last quarter. AustralianSuper Pty Ltd boosted its position in shares of Edwards Lifesciences by 17.8% during the third quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock valued at $216,013,000 after buying an additional 494,604 shares during the period. Ownership Capital B.V. grew its stake in shares of Edwards Lifesciences by 1.2% during the third quarter. Ownership Capital B.V. now owns 2,993,019 shares of the medical research company’s stock valued at $197,509,000 after buying an additional 34,597 shares during the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Edwards Lifesciences by 2.1% during the second quarter. American Century Companies Inc. now owns 2,082,961 shares of the medical research company’s stock valued at $192,403,000 after buying an additional 43,247 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on EW shares. Daiwa Capital Markets upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Stifel Nicolaus decreased their price objective on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a report on Thursday, July 25th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, TD Cowen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $100.00 to $70.00 in a research note on Thursday, July 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $75.67.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,000 shares of company stock worth $2,657,000. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $70.56 on Friday. The company has a market capitalization of $41.61 billion, a PE ratio of 10.18, a P/E/G ratio of 3.95 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a 50-day simple moving average of $67.66 and a two-hundred day simple moving average of $75.83. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm’s revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.59 earnings per share. Research analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.